Terms: = Uterine cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
68 results:
1. Diagnosis and rescue of malignant hyperthermia induced by anesthesia during radical surgery in a cervical cancer patient using the National Remote Emergency System: A case report.
Xiao Y; Yu R; Gu J
Medicine (Baltimore); 2024 Apr; 103(16):e37699. PubMed ID: 38640306
[TBL] [Abstract] [Full Text] [Related]
2. Diffusion kurtosis imaging with multiple quantitative parameters for predicting microsatellite instability status of endometrial carcinoma.
Song Q; Dong W; Tian S; Xie L; Chen L; Wei Q; Liu A
Abdom Radiol (NY); 2023 Dec; 48(12):3746-3756. PubMed ID: 37740047
[TBL] [Abstract] [Full Text] [Related]
3. The Effect of a Myomectomy on Myoma-related Symptoms and Quality of Life: A Retrospective Cohort Study.
Don EE; Mijatovic V; van Eekelen R; Hehenkamp WJK; Huirne JAF
J Minim Invasive Gynecol; 2023 Nov; 30(11):897-904. PubMed ID: 37453499
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of bladder filling effects on the dose distribution during radiotherapy for cervical cancer based on daily CT images.
Zhang F; Zhou M; Wang G; Li X; Yue L; Deng L; Chi K; Chen K; Qi Z; Deng X; Peng Y; Liu Y
J Appl Clin Med Phys; 2023 Nov; 24(11):e14097. PubMed ID: 37438966
[TBL] [Abstract] [Full Text] [Related]
5. Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins.
Kulkarni A; Wright NMA; Forget AN; Ramsay T; Mallick R; Weberpals JI
Cancer Med; 2023 Aug; 12(15):16173-16180. PubMed ID: 37417528
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness of Myomectomy versus Hysterectomy in Women with uterine Fibroids.
Thao V; Moriarty JP; Stewart EA; Borah BJ
J Minim Invasive Gynecol; 2023 Oct; 30(10):813-819. PubMed ID: 37286130
[TBL] [Abstract] [Full Text] [Related]
7. Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer.
Jiang Y; Wang J; Jiang P; Wang X; Zhang L; Zhang Y
BMC Cancer; 2023 May; 23(1):481. PubMed ID: 37245053
[TBL] [Abstract] [Full Text] [Related]
8. Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study.
Zhao XL; Zhao S; Xia CF; Hu SY; Duan XZ; Liu ZH; Wang YY; You TT; Gao M; Qiao YL; Basu P; Zhao FH
BMC Med; 2023 Apr; 21(1):149. PubMed ID: 37069602
[TBL] [Abstract] [Full Text] [Related]
9. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
[TBL] [Abstract] [Full Text] [Related]
10. The WID-EC test for the detection and risk prediction of endometrial cancer.
Barrett JE; Jones A; Evans I; Herzog C; Reisel D; Olaitan A; Mould T; MacDonald N; Doufekas K; Newton C; Crosbie EJ; Bjørge L; Colombo N; Dostalek L; Costas L; Peremiquel-Trillas P; Ponce J; Matias-Guiu X; Zikan M; Cibula D; Wang J; Sundström K; Dillner J; Widschwendter M
Int J Cancer; 2023 May; 152(9):1977-1988. PubMed ID: 36533702
[TBL] [Abstract] [Full Text] [Related]
11. Significant decrease of a master regulator of genes (REST/NRSF) in high-grade squamous intraepithelial lesion and cervical cancer.
Cortés-Sarabia K; Alarcón-Romero LDC; Flores-Alfaro E; Illades-Aguiar B; Vences-Velázquez A; Mendoza-Catalán MÁ; Navarro-Tito N; Valdés J; Moreno-Godínez ME; Ortuño-Pineda C
Biomed J; 2021 Dec; 44(6 Suppl 2):S171-S178. PubMed ID: 35491677
[TBL] [Abstract] [Full Text] [Related]
12. Ultrasound Elastography under Deep Learning Algorithm to Analyze the Therapeutic Effect of Clustered Regularly Interspaced Short Palindromic Repeats Short Hairpin Ribonucleic Acid Nanoparticles on Cervical cancer.
Li M; Li W; Zhao L
J Healthc Eng; 2021; 2021():7538984. PubMed ID: 34880980
[TBL] [Abstract] [Full Text] [Related]
13. aldh2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
[TBL] [Abstract] [Full Text] [Related]
14. Should the management of high grade cervical squamous intraepithelial lesion (HSIL) be different in HIV-positive women?
Gilles C; Velghe-Lenelle M; Manigart Y; Konopnicki D; Rozenberg S
AIDS Res Ther; 2021 Jul; 18(1):44. PubMed ID: 34301269
[TBL] [Abstract] [Full Text] [Related]
15. Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study.
Tanaka LF; Schriefer D; Radde K; Schauberger G; Klug SJ
PLoS One; 2021; 16(7):e0253801. PubMed ID: 34260601
[TBL] [Abstract] [Full Text] [Related]
16. Villoglandular adenocarcinoma of the uterine cervix: a systematic review and meta-analysis.
Dietl AK; Beckmann MW; Aumann K
Arch Gynecol Obstet; 2021 Aug; 304(2):317-327. PubMed ID: 34036437
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
[TBL] [Abstract] [Full Text] [Related]
18. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract] [Full Text] [Related]
19. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
[TBL] [Abstract] [Full Text] [Related]
20. Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB-IIA cervical cancer with risk of recurrence.
Zhu J; Lou R; Ji S; Wu G; Chen Q; Hu Q; Zhao Y; Cai D; Gu K
Anticancer Drugs; 2021 Feb; 32(2):203-209. PubMed ID: 33186140
[TBL] [Abstract] [Full Text] [Related]
[Next]
